Leveraging nanochannels for universal, zero-order drug delivery in vivo

Silvia Ferrati, Daniel Fine, Junping You, Enrica De Rosa, Lee Hudson, Erika Zabre, Sharath Hosali, Li Zhang, Catherine Hickman, Shyam Sunder Bansal, Andrea M. Cordero-Reyes, Thomas Geninatti, Juliana Sih, Randy Goodall, Ganesh Palapattu, Malgorzata Kloc, Rafik M. Ghobrial, Mauro Ferrari, Alessandro Grattoni

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


Drug delivery is essential to achieve effective therapy. Herein we report on the only implantable nanochannel membrane with geometrically defined channels as small as 2.5 nm that achieves constant drug delivery in vivo. Nanochannels passively control the release of molecules by physico-electrostatic confinement, thereby leading to constant drug diffusion. We utilize a novel design algorithm to select the optimal nanochannel size for each therapeutic agent. Using nanochannels as small as 3.6 and 20 nm, we achieve sustained and constant plasma levels of leuprolide, interferon α-2b, letrozole, Y-27632, octreotide, and human growth hormone, all delivered at clinically-relevant doses. The device was demonstrated in dogs, rats, and mice and was capable of sustaining target doses for up to 70 days. To provide evidence of therapeutic efficacy, we successfully combined nanochannel delivery with a RhoA pathway inhibitor to prevent chronic rejection of cardiac allografts in a rat model. Our results provide evidence that the nanochannel platform has the potential to dramatically improve long-term therapies for chronic conditions.

Original languageEnglish (US)
Pages (from-to)1011-1019
Number of pages9
JournalJournal of Controlled Release
Issue number3
StatePublished - 2013


  • Drug delivery
  • Implantable device
  • Nanochannel
  • Transplantation

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Leveraging nanochannels for universal, zero-order drug delivery in vivo'. Together they form a unique fingerprint.

Cite this